The Role of Kallikrein10 (KLK10) Polymorphism in Prostate Cancer Susceptibility KLK10 polymorphism in Prostate Cancer
Vol. 19 No. 01 (2022),
Purpose: The present study aims to investigate the potential role of Kallikrein 10 (KLK10) genotype and allele frequencies in predisposition to prostate cancer.
Materials and Methods: KLK10 (rs7259451) gene polymorphisms were determined by real-time polymerase chain reaction analysis in patients with prostate cancer (n=69) and controls (n=76).
Results: KLK10 gene frequencies were significantly different in the case and control groups (P = .028). GG carriers were significantly higher in the control group (P = .034), whereas TT carriers were higher in the prostate cancer group (P = .033). Furthermore, The patients with GG genotype had the lowest PSA levels while TT carriers had the highest (P = .005).
Conclusion: According to the results, we suggested that carrying variant T allele and also carrying homozygote TT genotype could be a potential risk, while ancestral homozygote GG genotype and G allele are risk reducing factors for prostate cancer.
- Prostate cancer, polymorphism, KLK10 gene; rs7259451
How to Cite
Siegel RL, Miller KD, Jemal A. CA Cancer J Clin 2016; 66: 7–30.
Cintra HS, Pinezi JC, Machado GD, et al. Investigation of genetic polymorphisms related to the outcome of radiotherapy for prostate cancer patients. Dis Markers. 2013;35:701-10.
Ostrander EA, Stanford JL. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet. 2000;67:1367-75.
Lai J, Kedda MA, Hinze K, et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 2007,28: 1032-39.
Rahimi N, Azizi M, Bahari G, Narouie B, Hashemi M. Association of EGLN2 rs10680577 Polymorphism with the Risk and Clinicopathological Features of Patients with Prostate Cancer.. Asian Pac J Cancer Prev. 2020;21:1221-26.
Shaik AP, Jamil K, Das P. CYP1A1 Polymorphisms and Risk of Prostate Cancer: A Meta-analysis. Urol J. 2009;6,78-86.
Simforoosh N, Dadpour M, Mousapour P, Shafiee A, Hashemi BM. Factors Predicting Prostate Specific Antigen Failure Following Radical Prostatectomy: Experience with 961 Patients. Urol J. 2020;17, 486-91.
Borgoño CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res. 2004;2: 257-80.
Zhang Y, Bhat I, Zeng M, et al. Human kallikrein 10, a predictive marker for breast cancer. Biol Chem. 2006;387:715-21.
Planque C, Aïnciburu M, Heuzé-Vourc'h N, Régina S, Monte M, Courty Y. Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues. Biol Chem. 2006;387:783-8.
Yousef GM, Polymeris ME, Yacoub GM, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 2003; 63: 2223-27.
Bayani J, Paliouras M, Planque C, et al. Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. Mol Oncol. 2008;2:250-60.
Angelopoulou K, Karagiannis GS. The canine kallikrein-related peptidases 9 and 10: structural characterization and expression in mammary cancer. Mamm Genome. 2009; 20:758-67.
Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53:1423-32.
Yousef GM, White NM, Michael IP, et al. Identification of new splice variants and differential expression of the human kallikrein 10 gene, a candidate cancer biomarker. Tumour Biol. 2005;26: 227-35.
Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol. 2005;26:324-36.
Luo LY, Bunting P, Scorilas A, Diamandis EP. Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin Chim Acta. 2001;306:111-18.
Bharaj BB, Luo LY, Jung K, Stephan C, Diamandis EP. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. Prostate 2002;51: 35-41.
Batra J, Tan OL, O’Mara T, et al. Kallikrein-Related Peptidase 10 (KLK10) Expression and Single Nucleotide Polymorphisms in Ovarian Cancer Survival. Int J Gynecol Cancer 2010;20:529-36.
- Abstract Viewed: 0 times
- 6425/pdf Downloaded: 0 times